⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

CTS Corp CEO Kieran O'Sullivan sells $2.36 million in stock

Published 12/05/2024, 03:00 AM
CTS
-

Kieran O'Sullivan, President and CEO of CTS Corp (NYSE:CTS), a company with a market capitalization of $1.66 billion and a strong year-to-date return of ~27%, sold a significant portion of his holdings in the company, according to a recent SEC filing. According to InvestingPro analysis, CTS currently trades above its Fair Value. On December 2 and 3, O'Sullivan sold a total of 42,393 shares of common stock, generating proceeds of approximately $2.36 million. The sales were executed as part of a pre-arranged 10b5-1 trading plan, with prices ranging from $55.5736 to $55.815 per share. Following these transactions, O'Sullivan retains ownership of 413,250 shares in the company. The stock has demonstrated robust performance with a 38% return over the past year, and InvestingPro data shows the company maintains a "GOOD" financial health score, with liquid assets exceeding short-term obligations. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.

In other recent news, CTS Corporation reported a mixed set of financial results for its third quarter of 2024. The company's revenue saw a slight dip of 1.6% compared to the same quarter last year, totaling $132 million, while adjusted earnings per share rose by 17% year-over-year to $0.63. Despite these mixed results, CTS Corporation highlighted a strong performance in diversified markets, which now account for 52% of total revenue.

In addition, the successful acquisition of SyQwest is expected to contribute to future revenue growth. This acquisition has already contributed $3.6 million in sales. However, transportation sales declined by 17% due to softer demand and regional dynamics.

CTS Corporation has also adjusted its full-year revenue guidance to between $515 million and $525 million, while maintaining its adjusted diluted earnings per share guidance at $2.05 to $2.25. While the company anticipates softness in medical markets in the fourth quarter due to inventory management, it remains focused on cash generation, strategic growth, and disciplined acquisitions. These are recent developments in the company's financial performance and strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.